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The innate immune system constitutes the first line of defense against invading
pathogens, regulating the normal microbiota and contributes to homeostasis. Today
we have obtained detailed knowledge on receptors, signaling pathways, and effector
molecules of innate immunity. Our research constellation has focused on ways to induce
the expression of antimicrobial peptides (AMPs), the production of oxygen species
(ROS and NO), and to activate autophagy, during the last two decades. These innate
effectors, with different mechanisms of action, constitute a powerful defense armament
in phagocytes and in epithelial cells. Innate immunity does not only protect the host
from invading pathogens, but also regulates the composition of the microbiota, which
is an area of intense research. Notably, some virulent bacteria have the capacity to
downregulate innate defenses and can thereby cause invasive disease. Understanding
the detailed mechanisms behind pathogen-mediated suppression of innate effectors are
currently in progress. This information can be of importance for the development of
novel treatments based on counteraction of the downregulation; we have designated
this type of treatment as host directed therapy (HDT). The concept to boost innate
immunity may be particularly relevant as many pathogens are developing resistance
against classical antibiotics. Many pathogens that are resistant to antibiotics are sensitive
to the endogenous effectors included in early host defenses, which contain multiple
effectors working in cooperation to control infections. Here, we review recent data
related to downregulation of AMPs by pathogenic bacteria, induction of innate effector
mechanisms, including cytokine-mediated effects, repurposed drugs and the role of
antibiotics as direct modulators of host responses. These findings can form a platform
for the development of novel treatment strategies against infection and/or inflammation.
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INTRODUCTION
After Alexander Fleming first discovered penicillin, several generations of different types of classical
antibiotic drugs were developed. Most of these antibiotics target a specific molecule or an essential
mechanism needed for survival of the bacterium. However, the targets of antibiotics can be
altered by mutations, rendering them ineffective in controlling the infection. Bacterial enzymes
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can also degrade active antibiotics, and membrane proteins can
pump the antibiotic drug out of the bacterial cell and thus
prevent it from reaching the intended target. Genes encoding
the degrading enzymes and the membrane pumps can be located
on plasmids that are horizontally transferred between bacterial
strains (1, 2). Excessive antibiotic usage has exerted a selection
pressure on the bacterial population, which has increased the
spread of antibiotic resistant strains. Although novel antibiotics
have been developed the selection of resistance continues, and
in recent years, antibiotic resistance has increasingly resulted
in prominent problems for healthcare worldwide. Excessive use
and abuse of antibiotics are major drivers of antimicrobial
resistance (AMR). Livestock and agriculture industries are, for
example, major contributors to AMR, due to the application
of medically important antibiotics in livestock production and
in the food/agriculture industry (3, 4). A critical scenario
may emerge with the spread of resistant bacterial strains that
no classical antibiotics exhibit activity against, i.e., pan-drug-
resistant (PDR) pathogens. Consequently, we are entering an
era similar to the pre-antibiotic time, where common infections
would be serious or even lethal. Thus, there is an urgent need to
find novel strategies to prevent and control infection.
Various alternative strategies have been suggested, including
blockage of host microbe interactions, inhibition of virulence
factors, and the development of bacterial phage therapy (5). All
these approaches have potential but have not yet resulted in
therapies that can be utilized in a clinical setting. Furthermore,
any single target strategy would theoretically select for resistant
bacteria, since novel resistance mechanisms are likely to occur
upon application of a new treatment. The consequences of
resistance to treatments could be disastrous and thus, the
application of new or adapted treatments should be critically
studied before introduction into clinical settings.
We have developed a strategy based on direct stimulation
of host cells by activation of endogenous defense mechanisms,
such as antimicrobial peptides (AMPs), reactive oxygen species
(ROS and NO) and autophagy, in both epithelial cells and
macrophages. These are early immune mechanisms aiming to
limit the spread of pathogens by killing them [(6–8); Figure 1].
Pathogens have developed different mechanisms to evade the first
FIGURE 1 | (A) The composition of the normal gut microbiota is dependent on expression of AMPs. Mucins are indicated by the gray zone at the apical site of the
cells and AMPs by symbols ( ). (B) Some pathogens ( ) can downregulate the expression of AMPs and disrupt the epithelial barriers. (C) Downregulation
can be counteracted by inducers ( ). (D) The pathogens are eliminated when AMP expression is restored.
line of defense and are often not metabolically adapted to a life in
the external environment like the lumen of the gut, but instead
they need to invade and exploit the host tissues (9). However,
counteracting the pathogen-mediated downregulation on host
cells by recapturing the expression of innate antimicrobial
effectors can lead to elimination of the pathogenic intruder
(Figure 1). Interestingly, by this strategy, it is possible to induce
multiple genes, generating a powerful response of innate effectors
in cells. The genes encoding response factors are co-regulated
in an orchestrated fashion to create effective responses and are
selected for even in early eukaryotic lifeforms. The simultaneous
induction of multiple effectors is the key for this strategy,
since the combination should limit the selection of resistant
pathogenic strains.
Alternative strategies based on direct application of AMPs
have been in development. First, topical treatment using
modified peptides on skin infections, relying on direct
antimicrobial activity have been presented (10). However,
the use of a single peptide would be expected to select for
resistant strains. Furthermore, modified AMPs have also been
used as injections for immune modulation of the peptides, in
order to modify innate responses (11). This second strategy has
been reviewed elsewhere (12).
Our approach of using induction of innate immunity with
emphasis on the expression of AMPs has resulted in inducers
that stimulate a range of innate antimicrobial effectors with
limited inflammation. The initial inducers we have studied are
butyrate and phenylbutyrate (PBA), which are effective in animal
models (6, 13). In human trials, PBA has been used together
with vitamin D3 as adjunct therapy to boost immunity against
Mycobacterium tuberculosis (Mtb) with a beneficial outcome
(14). An additional clinical trial utilizing butyrate as adjunct
therapy to treat shigellosis showed early reduction of local
inflammation (15). Our aim is to develop inducers with optimal
properties to activate innate effector mechanisms as host directed
therapies (HDTs) to combat infection in the absence of the
selection of resistant strains. In addition, a combination of HDTs
and classical antibiotics might enhance the treatment efficacy
and shorten the duration of antibiotic usage. Indeed, cooperative
action between classical antibiotics and innate antimicrobial
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effectors has been confirmed in vitro (16). These combination
therapies could retrieve usage of early generations of classical
antibiotics and would be in line with improved stewardship,
aiming to limit the spread of resistant strains.
Our focus in this review will be induction of antimicrobial
effector mechanisms in mucosal epithelial cells and phagocytes
of the macrophage lineage.
INNATE IMMUNITY AND FRONT LINE
DEFENSES
Innate immunity constitutes the first line of defense and includes
specific cells that produce various effector molecules to activate
mechanisms resulting in the elimination of pathogens. Different
cells of hematopoietic origin constitute the effector cells of
innate immunity, such as NK cells and dendritic cells, as well
as the professional phagocytic cells monocytes/macrophages and
granulocytes. Furthermore, the epithelial cells, while of non-
hematopoietic origin, are of fundamental importance, making
up a vital surface layer and working as a continuous defense
barrier. In our models, the target cells of innate induction have
been epithelial cells and macrophages (6, 14). Epithelial cells
are sewed and tilted together with tight junctions and adherent
junctions, respectively. These linkages between epithelial cells
have organ specific adaptations depending on the function of
the tissues, such as uptake of nutrients in the small intestine,
gas exchange in the lung, and filtration of the blood in
the kidney. Moreover, controlled para-cellular transport can
also occur. In innate immunity, epithelial cells are functional
players and constitutively secrete innate antimicrobial effectors,
keeping microbes at bay. Epithelial cells signal to internal
sites, secrete specific cytokines, and contribute to defense in
the local environment. If microbes pass the epithelial barrier,
macrophages, and dendritic cells in the underlying tissue
serve as defense mediators with links to adaptive immunity.
Further recruitment of neutrophils and monocytes represent
another wave of active antimicrobial defenses, originating from
the circulation. Innate lymphoid cells (ILCs) are essential in
this context, especially in the gut. They sense immunological
mediators that are released from epithelial cells and secrete
the specific cytokines IL-22 and IL-17 that in turn enhance
the secretion of epithelial antimicrobial peptides (17). Indeed,
the ILCs have been indicted as important local orchestrators
of environmental signals to an immune response for the
maintenance of homeostasis. This underlines that the initial
defenses rely on a complex network of cell communication (18).
AMPs and reactive radicals, such as nitric oxide (NO) and
oxygen species (ROS) with the capacity to eliminate invading
pathogens are some of the effector molecules produced by
epithelial cells and phagocytes. The combination of these effector
systems characterized best in phagocytes, and a similar system
operates on epithelial surfaces. Together these effectors work
in cooperation in either an additive or a synergistic manner as
an efficient armament against microbes. Notably, these effector
molecules are evolutionary ancient and have co-evolved with
the natural microbiota and have done so without selecting for
invasive resistant bacterial strains. This is in contrast to the
situation with classical antibiotics that have been only been
used for several decades and their usage has selected multiple
resistant strains.
Innate effectors, such as AMPs, are not only included in
the armament for killing pathogenic intruders but work also
as modulators of cell activity. In this respect, AMPs resemble
cytokines and chemokines by activating and recruiting different
immune cells. Interestingly, this dual activity has been described
for several AMPs, indicating a common character. Some AMPs
constitute links to adaptive immunity for specific responses and
memory functions. As an example, the human cathelicidin LL-37
is chemotactic to human T cells (19), and human beta-defensins
can recruit immature dendritic cells and memory T cells (20).
Molecules of the adaptive arm of immunity are also included in
front line defenses, such as IgA antibodies, that are secreted into
the mucosa and make up an efficient barrier together with innate
effector molecules. This underlines the cooperation between
adaptive and innate immunity at epithelial mucosal surfaces,
including multiple effectors for efficient protection of the tissues.
It is of importance to consider the turnover and differentiation
of epithelial cells and phagocytes, since the cells have to reach
maturity for full activity. Epithelial cells are derived from basal
cells in the lungs (21) and from crypt stem cells in the small
intestine (22). Upon maturation, epithelial cells use tight, and
adherent junction proteins for linking together adjacent cells
and seal off the interior tissues from the outside, allowing only
small molecules to pass in specific situations. Therefore, tight
junctions define a physical character of the epithelial barrier
that is important for innate defenses. Microbes do not pass the
para-cellular space, with the exception of certain pathogens that
actively break the barrier to enter (20, 23, 24). Epithelial cells are
exposed to friction and stress and hence are shed continuously
and must be renewed. The timing of this is dependent on the
specific epithelia. In the small intestine, epithelial cells have a
lifespan of∼4 days and in the lung, they last for over 4 weeks (25,
26). The removal of infected cells and renewal of the epithelial
cells will maintain active innate defenses. The high turnover of
epithelial cells is thus vital for an efficient barrier protection.
Neutrophils are potent phagocytes loaded with a dazzling
array of antimicrobial effector molecules. These cells, of
hematopoietic origin, differentiate from the bone marrow and
enter the circulation as mature phagocytes. The lifetime of
the neutrophils is short in the circulation. If they get alarmed
through chemotaxis by bacterial compounds, such as N-formyl-
MetLeuPhe (fMLF), they will transmigrate from the blood to the
site of infection loaded with effectors and exert their functions
by phagocytosis of microbes or by release of antimicrobial
molecules. It should be mentioned that mouse neutrophilic
granulocytes do not produce alpha-defensins, thus questioning
results frommouse models as responses in human with reference
to studies of these AMPs (27).
As indicated above, mature epithelial cells and phagocytes
are constantly alert and ready to kill microbes by constitutive
expression of genes encoding antimicrobial effectors. However,
both epithelial cells and phagocytes must be activated to enhance
the expression of innate immune effectors. Several pathogens
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suppress these immune effectors as part of their virulence in
order to invade the body.
DOWNREGULATION OF AMP
EXPRESSION
The gut microbiota plays a major role in the maintenance of
the overall health of the host. AMPs and additional innate
effector molecules are generally produced by epithelial cells
as well as by circulating inflammatory cells. The epithelial-
derived AMP-based defense system has co-evolved with diverse
microorganisms and has been shown to regulate the composition
of the commensal microbiota (28, 29). Expression of AMPs in
the gastrointestinal tract is considered constitutive and has a
symbiotic relation to the microbiota. It appears that the natural
microbiota is partially spared from the lethal action of AMPs
and certain bacteria have adapted resistance. One potential
mechanism by which the commensal microbiota reduce their
susceptibility to AMPs is by membrane modification, reducing
the net negative charge of the bacterial surface, thus decreasing
the interactions with AMPs (30). The unique microbiome
composition of an individual host is influenced by multiple
factors, including the use of specific drugs and antibiotics.
Interestingly, activation of endogenous AMPs can eliminate
pathogenic bacteria and promote a balanced microbiota in
the gut, while conventional antibiotics non-selectively decrease
bacterial numbers and diversity in the gut (31).
Different bacterial species thrive in the luminal milieu of
the intestinal tract and the microbiota of the gut has evolved
by metabolic adaptations. The microbial ecosystems produce a
spectrum of metabolites within the human host with diverse
functions. Many of these metabolites with specific functions
have been characterized and have the ability to limit the
growth of surrounding bacteria. The natural microbiota lacks
virulence factors needed to break through the epithelium (9).
In addition, there is interspecies competition and regulation of
the composition between the different bacteria of the natural
microbiota. Interestingly, the expression of surface defense
molecules is regulated by the microbiota that secrete metabolic
products, such as butyrate and lithocholic acid (LCA) (32).
Bacterial products modulate the expression of defense molecules
that in turn regulate the composition of the microbiota. Butyrate,
a short chain fatty acid (SCFA), is produced by fermentation of
starches, dietary fiber, sugars, and glycosylated proteins by the
intestinal microbiota.
Pathogens exhibit different metabolic adaptation compared
to the natural microbiota, and several pathogens have evolved
strategies, making them resistant to AMPs [reviewed in
Duperthuy (33)]. These strategies include modifications of
lipopolysaccharide, modifications of phospholipids, efflux pumps
and proteolytic degradation of AMPs. Interestingly, some
pathogens in contact with AMPs at low concentration can induce
resistant mechanisms and major virulence factors, which would
promote their invasive potential.
Furthermore, many pathogenic bacteria have evolved
mechanisms to invade the tissue by sophisticated mechanisms
to break through the mucosal epithelial barrier in order to
avoid or circumvent the defense pathways. We first reported
down-regulation of LL-37 and human beta-defensin-1 (HBD-1)
expression in human biopsies of patients with early stage of
Shigella infection (34). Plasmid DNA appeared to be responsible
for turning off the expression of these AMPs in the epithelial
surface as a virulence strategy to escape the immune surveillance.
Others also confirmed the downregulation of AMPs, and
secreted proteins were claimed to be the mediators responsible
for this downregulation (35). As a proof-of-principle, using an
animal model of shigellosis, we were able to demonstrate that
Shigella spp. down-regulated CAP-18 (rabbit cathelicidin) in
the large intestine, at the site of infection (13). Interestingly,
downregulation of CAP-18 was also observed in remote epithelial
lining of lungs and trachea, where no infection occurred (6).
Later, it was shown that Vibrio cholerae and enterotoxigenic
Escherichia coli (ETEC) suppress LL-37 and HBD-1 expression
in intestinal epithelial cells through the actions of cholera toxin
(CT) and labile toxin (LT), respectively (36). A similar scenario
was observed in patients with cholera and ETEC diarrhea
during early infection (37). Furthermore, our group showed
that pathogenic strains of Neisseria gonorrhoeae downregulated
the expression of LL-37 in a human cervical epithelial cell
line, while non-pathogenic or heat killed pathogenic strains of
Neisseria did not have such an effect. This result suggested a
survival strategy of the pathogen during invasion of the genital
tract (38). In experimental studies, we further demonstrated
that Vibrio cholera or enteropathogenic E. coli (EPEC) also can
downregulate CAP-18 in the small intestinal epithelia (39, 40).
These studies led to the conclusion that counteracting or
blocking pathogen-mediated down-regulation of endogenous
AMPs could be used for treatment of infections. Various small
molecular compounds are known to induce endogenous AMPs,
where immunomodulatory properties could be harnessed to treat
infections. Host directed therapy (HDT) against pathogens by
boosting the expression of endogenous AMPs is thus considered
as a novel alternative for treatment of infectious diseases
(Figure 1).
INDUCTION OF INNATE EFFECTORS IN
PHAGOCYTES AND EPITHELIUM
AMPs are potent antibacterial substances with activity
comparable to classical antibiotics. Initially it was suggested that
the peptides could be utilized in therapy as direct antimicrobial
substances. The disadvantage with this approach is that the
peptides are enzymatically degraded in the gastrointestinal tract,
and when injected they might evoke production of antibodies,
limiting the usage to topical administration for skin infections
and treatment of wounds. Furthermore, monotherapy with
single synthetic peptides could lead to selection of resistant
strains (41). Therefore, our logical approach was to stimulate
AMP production by activating regulatory pathways in the cells,
without stimulating inflammatory responses through NFκB.
This would result in induction of several genes encoding active
peptides, mimicking the true response in our front-line defenses
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(42). Accordingly, small molecules that can be administrated
orally have been used as inducers of AMP-expression both in
vitro and in vivo. By this strategy multiple peptides with different
killing mechanisms together with NO and ROS would be
engaged, making selection of resistant bacterial strains unlikely.
These small inducing molecules can enter the blood stream and
have systemic effects, as well as also boosting innate defenses at
mucosal surfaces and in phagocytic cells (6, 43–46).
The idea to improve mucosal defenses was proposed by
Fehlbaum et al. (47) where they showed that isoleucine could
induce transcription of human beta defensin 2 in bovine
epithelial cells. Shortly after this, we identified butyrate as a major
inducer of AMP-expression (48, 49). Butyrate is a product of
fiber fermentation by the natural microbiota and the carbon
energy source for colonic epithelial cells. Butyrate is known
to be an HDAC inhibitor and has earlier been used in a
Shigella infection model with beneficial effects (50). However, the
mechanisms underlying these beneficial effects remained elusive
at that time (51).
Today several of the inducers of AMP expression have
been identified as histone deacetylase inhibitors (HDACi) (52).
The activity relates to histone modifications, where histone
acetyltransferase (HAT) mediates acetylation of lysine residues,
resulting in reduced ionic interactions between the basic histones
and the acidic DNA with more open chromatin structure. In
contrast, HDAC reverses this reaction, and if inhibited the
histones aremaintained in the acetylated form. Therefore, HDAC
inhibition affect the chromatin structure from tightly packed
toward open with enhanced access of different transcription
factors and machinery for transcription, including the RNA
polymerase II. Typically, the responses to HDACi are complex
and involve many genes, and some pathways of HDACi are
physiologically relevant. Butyrate is considered an important
part of the normal human physiology together with other short
chain fatty acids (SCFA), enhancing the expression of mucins
andAMPs in intestinal epithelial cells. SCFAs strengthen defenses
and enhance epithelial functions by increasing tight junctions
and thus maintaining barrier integrity. Various bacterial species
produce butyrate in the human colon, most of them belong
to the Firmicutes phylum, in particular the clostridial clusters
IV and XIVa, which have been associated with a healthy gut
homeostasis (53). Altered composition of the microbiota with
reduced growth of butyrogenic Clostridium species has been
linked to susceptibility to infections and inflammation (54).
Butyrate also affects various immune cells in the gut with
beneficial effects of the host, balancing inflammatory reactions
to homeostasis of host microbe interactions in the gut (55). The
specific receptors of butyrate GPR41 (FFAR3) and GPR43 (FFA2)
are G-protein coupled receptors that have been characterized on
several immune cells (56). The anti-inflammatory properties of
butyrate have been shown to be dependent on the expression
of GPR43 in regulatory T-cells (57). Butyrate can also enter
cells for example via the SLC5A8 transporter (58), which is
needed for the HDACi activity. In summary, both the HDACi
and receptor activation by butyrate are needed for imparting
the beneficial effects of butyrate, leading to enhanced barrier
integrity (59).
The concentration of butyrate in the gut is 2.3–26.1 mmol/kg,
while it is 1–64µM (60) in the blood stream. Accordingly,
butyrate can be absorbed from the colon, and affect remote
organs, which we have shown for the pancreas and the
lungs (6, 44).
Butyrate is a foul-smelling compound and is not possible to
use it as an oral drug. Therefore, we searched for alternative
compounds and identified phenyl-butyrate (PBA), a drug already
approved for treatment of urea cycle disorders by virtue of
the ammonium scavenging capacity (61). Importantly, PBA is
available in tablet form and using animal models, we have
confirmed that it has a similar induction profile of AMPs as
butyrate (6). It is also an HDACi as well as a chemical chaperone
(62). Since PBA is a registered drug for clinical use, all toxicity,
and regulatory studies have already been performed and thus,
it could enter the clinic in a fast track for additional indications
(Phase IIB-trials).
The most recent research on butyrate further underlines
its important role. In a mouse model, butyrate was found to
imprint antimicrobial programs in macrophages (63). Butyrate
was demonstrated to increase antimicrobial activity, reduce
mTOR kinase activity, increase LC3-associated host defense,
as well as enhancing AMP expression without increasing
the production of inflammatory cytokines. The antimicrobial
response was dependent on HDAC3-expression, which was
shown by blocking specific transcription using siRNA (63). In
line with this result, butyrate was shown to protect intestinal
epithelial cells from damage caused by Clostridium difficile in
a mouse model (64). This effect was mediated by stabilization
of the transcription factor HIF-1α, resulting in attenuated
inflammation and improved intestinal barrier. Thus, butyrate is
a key player in host defense against inflammation and infections
(64). The pathway involving HIF1α has also been shown to be
important in the inhibition of Candida albicans by commensal
bacteria, where cathelicidin was highlighted as an important
contributor (65).
HDAC inhibition has long been known and, as the name
indicates, relates originally to the effect on histones and
chromatin structure. In recent years, acetylation has been shown
to be much broader, comprising many non-histone proteins.
These proteins are involved in key cellular events including
signal transduction, autophagy, metabolism, protein folding, and
cell division (66). Accordingly, the acetylation was renamed to
lysine acetyltransferase (KAT) and lysine deacetylase (KDAC)
to underline broader targets. These epigenetic mechanisms have
recently been thoroughly reviewed in relation to innate immunity
and infections (67). Clearly, the regulatory circuits of HDACi,
or rather KDACi, in relation to induction of AMPs are complex
and many specific details are still to be clarified. Therapeutic
interventions enhancing defenses by affecting these regulatory
pathways to prevent or fight infections are thus worth pursuing.
Adverse effects have been of concern for HDACi and must be
considered for each inducing compounds. However, HDACi is a
part of our physiology exemplified by the production and release
of butyrate in the gut.
We have shown co-operative inducing activity between
butyrate/PBA and vitamin D3 on the expression of the CAMP
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gene encoding LL-37 in lung and gut epithelium (68). The
cooperativity with respect to the CAMP gene relates most likely
to effects on different regions of the promoter. Interestingly, in
lung epithelial cells with the VDR expression knocked-down by
siRNA, the induction of the CAMP gene by PBA and butyrate
was reduced (69). Butyrate and PBA likely altered chromatin
structure and thus increased the access of VDR to the CAMP
gene promoter. PBA and butyrate are not cognate ligands to
VDR, but acetylation of components in the signal transduction
pathway of VDR is the most likely explanation for the observed
cooperative effect.
Vitamin D3, a nutritional component, has been shown to
be a potent AMP inducer. This activity of vitamin D3 was
originally found in a general screen of vitamin D3 induced genes.
The induction of the CAMP gene expression was outstanding
compared to other affected genes identified (70). Subsequently,
the effects of vitamin D3 on AMP-expression in relation to
tuberculosis (TB) and leprosy were demonstrated both in
vitro and in vivo (71), and the anti-mycobacterial activity was
dependent on the CAMP gene (72). Binding of the vitamin
D receptor (VDR) to the promoter of the CAMP gene, with
subsequent production of the human cathelicidin LL-37, was
shown by Gombart et al. (73) and more specifically in the skin by
Weber et al. (74). Importantly, the vitamin D3 effect was specific
for cathelicidin-expression in primates and was dependent on
a transposable element that entered the gene late in evolution
(75). Rodents do not have this insertion element and hence
the mouse has not been a suitable in vivo model for vitamin
D-mediated responses against infections. However, a mouse
model of the vitamin D-induced human cathelicidin was recently
generated. This transgenic mouse has some of the features seen
in humans after vitamin D3 induction, with enhanced killing of
Staphylococcus aureus, as well as induced CAMP gene expression
following topical induction in the skin (76).
Notably, vitamin D3 has been known to induce the
differentiation of monocytes into macrophages. The presence
of vitamin D during differentiation promotes the expression
of cathelicidin and intracellular control of mycobacterial
growth (77, 78).
The observation of the synergy between PBA and vitamin
D, together with the potent effect of CAMP expression in the
lung epithelial cell-line VA10, and against Mtb prompted us
to continue with clinical studies. Previous clinical trials using
vitamin D as an adjunctive therapy together with standard TB-
treatment have failed to show positive effects on pre-specified
clinically relevant endpoints (79). However, a significant effect
on time to sputum culture conversion was observed when a
polymorphic variant (TT genotype) of the VDR receptor variant
TaqI was present (80).
Interestingly, in our study using PBA and vitamin D as
adjunct therapy together with the four classical TB drugs
Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide, enhanced
the antibiotic activity. Furthermore, the outcome was significant
for sputum clearance together with a decline in clinical score.
These results indicate that host directed therapy is effective
against difficult to treat infections (14).
Additional inducers would be of interest to broaden our
concept for host directed therapy. We therefore set up a strategy
to screen for novel inducers that included the development of
a reporter-system cell line containing the CAMP gene fused to
luciferase (52). The initial screen was with a panel of HDAC
inhibitors followed by a Prestwick library of 1,200 compounds
of FDA approved drugs. Several compounds were identified
as CAMP gene inducers, but the HDACi Entinostat gave the
most prominently induced response at a low concentration
(2.5µM). Subsequently, we showed Entinostat to be effective
in animal models for Shigella and Vibrio cholera infections
(8, 40). Detailed analyses of the mechanism for induction of
Entinostat was dependent on the transcription factors STAT3 and
HIF1α. HIF1α was found bound to the CAMP gene promoter,
while STAT3 activates HIF1α (81), but the initial steps of the
activations are still not clarified. Since Entinostat is toxic at
high concentrations and has been developed as a cancer drug
candidate, we therefore made several variants of Entinostat called
aroylated phenylenediamines (APDs), with the aim to improve
water solubility and to reduce toxicity (8). Several of these non-
toxic lead compounds are active in inducing several AMP-genes
in colon and lung epithelial cells (8, 82). We are currently in
the process of developing these compounds further as drugs
for host directed therapy against infection. The approach is
to utilize these novel inducers alone or in combination with
conventional antibiotics.
The effects of vitamin D on the CAMP gene are well-
documented and relevant for Mycobacterium infections, both
leprosy and tuberculosis (71, 78). The vitamin D receptor (VDR)
binds to DNA as a heterodimer in complex with the retinoid X
receptor (RXR). The role of the RXR partner in this context has
not been defined in detail. Partners of class II nuclear receptors,
other than VDR, are farnesoid X receptor (FXR) and the retinoic
acid receptor (RAR). Interestingly, these partners are also linked
to AMP induction and innate immunity.
Bile acids are ligands to FXR that can induce CAMP gene
expression. The CAMP gene induction by FXR was initially
linked to biliary duct sterility (83). In mouse models, utilizing
knockout mice of the CYP27 gene with reduced bile synthesis
or knockout mice for the FXR gene (NR1H4 gene), a broader
effect of FXR was seen to regulate innate immunity in small
intestinal epithelial cells (84). FXR and bile acids regulated the
expression of several antimicrobial components and affected the
occludin protein of the tight junctions (84). Pronounced effects
of deleted FXR or reduced bile synthesis on antimicrobial activity
and bacterial translocation were observed. FXR has also been
highlighted in inflammation as counteracting TLR-4 mediated
response in myeloid cells (85).
Furthermore, the synthesis of retinoic acid, the ligand
for RAR/RXR heterodimer, has been linked to epithelial
transcription programs of defense. Commensal Clostridia species
can modulate retinoic acid availability by affecting the synthesis
and thereby the IL-22-dependent antimicrobial responses.
Bacterial regulation of retinoic acid synthesis was shown to be
important for the balance of the microbiota (86), indicating a role
for RAR/RXR in the homeostasis of the natural microbiota.
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FIGURE 2 | Summary of the main events in early defense by innate effector mechanisms described in the text. NR, nuclear receptor; HDACi, histone deacetylase
inhibition; AMPs, anti-microbial peptides; ROS, reactive oxygen species; NO, nitric oxide; iNOS, inducible nitric oxide synthase; ATG, autophagy related gene; HIF1α,
hypoxia-inducible factor 1-alpha; STAT3, signal transducer and activator of transcription 3; CP, cytoplasmic protein; Ac, acetylation; Histone-Ac, acetylated histone
and open chromatin.
Other orphan members of nuclear receptors with unknown
natural ligands have emerged as crucial regulators of
inflammation and immune responses (87), but are not directly
linked to induced expression of AMPs.
In summary, nuclear receptors and KDACs are sensors of
metabolites and nutritional components, regulating the status of
innate immunity. Together these proteins serve as sensors in the
epithelium at the interphase of the outside environment and the
tissue, where microbial exposure occurs. Both nuclear receptors
and KDACs can be affected by synthetic ligands and are thus
motives for enhancing defenses to prevent or fight infections
(Figure 2).
ACTIVATION OF AUTOPHAGY TO FIGHT
BACTERIAL INFECTION
Autophagy is a conserved mechanism to maintain homeostasis
and is tightly linked to cellular metabolism. It is also involved in
the cellular defense mechanisms against a range of intracellular
microbes. Several important primary pathogens, including Mtb,
Salmonella, and Legionella, have evolved mechanisms to avoid
or block the autophagic process (88). Thus, efforts to restore
autophagy by using small molecular drugs could be used to
fight infections against these bacteria. Here we will review recent
reports and results, including drugs that have been used for this
particular purpose.
Autophagy is a general concept that can be further subdivided
into macro-autophagy, mitophagy, xenophagy, LC3-associated
phagocytosis, and chaperone-mediated autophagy, with specific
but also overlapping functions (89). Here we will mainly discuss
xenophagy, which specifically targets bacteria (90).
Mtb specifically targets autophagy and blocks the fusion
between the phagosome and the lysosome (91, 92). This
mechanism facilitates the intracellular survival of Mtb in human
macrophages and is essential for the virulence of Mtb. Thus,
restoration of autophagy has been selected as a target for host-
directed therapies againstMtb. Several FDA-approved drugs with
the potential to restore autophagic function duringMtb-infection
have been identified. Vitamin D, for example, has been known to
have beneficial effects against Mtb since the pre-antibiotic time,
but the mechanisms have not been well-described. However, Liu
et al. (71) showed that intracellular control of Mtb growth is
regulated by vitamin D via the induction of the AMP LL-37.
LL-37 has direct anti-mycobacterial effects in vitro, but other
mechanisms may also be involved. One intriguing possibility is
that LL-37 acts as a mediator of autophagy activation (93), which
is a claim that has been further substantiated by our results,
showing that vitamin D activates autophagy via a paracrine
loop and activation of the surface associated P2X7-receptor
(7). In fact, the autophagy-related genes Atg5 and Beclin-1 are
induced by vitamin D in human macrophages (7, 93). It was
recently shown in a Helicobacter pylori-model that vitamin D
can restore lysosomal degradation by activation of the protein
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disulfide isomerase family A, member 3 (PDIA3) receptor
via upregulation of Ca++ channels, resulting in a normalized
lysosomal acidification (94).
Notably, the autophagy-activating effect of vitamin D is
further enhanced by the addition of PBA and the combined
effect of these compounds depends on LL-37 in order to
activate autophagy. The mechanism behind this effect involves
VDR-activation but most likely also chromatin remodeling
caused by the histone deacetylase effects exerted by PBA (7).
In addition, PBA alone has a direct growth inhibitory effect
on Mtb (95). Due to the promising effects of vitamin D on
autophagy and inhibition of Mtb growth in humanmacrophages,
several clinical trials of vitamin D supplementation as adjunctive
treatment to patients with pulmonary TB have been performed
(79). However, the clinical outcome in these trials have been
limited in relation to the primary endpoint (sputum culture
conversion). The combination of vitamin D with PBA resulted
in a faster conversion of sputum culture and better clinical
TB-score in two clinical trials (14, 96). Furthermore, some
positive effects of vitamin D3 have been observed with regard to
pre-selected secondary endpoints, including pro-inflammatory
cytokines (97).
The discrepancy between the in vitro results showing
beneficial effects of vitamin D3 and the mostly negative results
from clinical trials is intriguing. One reason for the lack of
effect of vitamin D3 in clinical TB-trials is that the standard
treatment is usually very effective, and any beneficial effect of
adjunctive vitamin D3 treatment would require a very large study
cohort to detect a statistically significant difference. Based on
these assumptions it has been proposed that the true benefit
of an adjunctive protocol with any immunomodulatory drug
would be found in trials on MDR TB-patients, where the
standard drug regimens are ineffective. In fact, a recent meta-
analysis comprising 1,850 participants in 8 interventional trials
found that vitamin D3 accelerated sputum culture conversion in
patients infected with MDR Mtb, but not in those patients with
susceptible Mtb isolates (79). Another important factor may be
the daily dose vs. bolus dose of vitamin D3 given over a period of
weeks or months, which may not be suitable to impart beneficial
impacts on the immune system to fight TB disease (14, 96).
Finally, vitamin D3 supplementation has been shown to exhibit
the best effect against respiratory tract infections in individuals
with prominent vitamin D3 deficiency (<25 nmol/L). However,
the beneficial effect was evident also in those individuals with
serum levels of 25 OH-vitamin D3 up to 75 nmol/L (98).
On the other hand, it has been shown that the common TB-
drugs isoniazid and pyrazinamide activate autophagy (99). The
beneficial effect of this in vitro finding remains to be shown in a
clinical context, but adds another layer of complexity to the story.
In addition to vitamin D3, several other drug-like compounds
have been identified in different screens for autophagy inducing
agents. For example, the anti-parasitic drug nitazoxanide,
the anti-depressive drug fluoxetine and the EGFR-inhibitor
gefitinib, have all been shown to activate autophagy. In
addition, the anti-epileptic drugs carbamazepine and valproic
acid also activate autophagy and impair Mtb growth in human
macrophages (100).
Autophagy is also important for host defense against other
bacteria, not classically considered to have an intracellular
lifestyle. One example is Klebsiella pneumoniae, where
downregulated or impaired autophagy leads to increased
bacterial growth and increased mortality in mice (101). However,
it should be noted that for some additional extracellular bacteria,
such as Staphylococcus aureus and Pseudomonas aeruginosa,
autophagy appears to be exploited by the pathogens to cause
disease. Consequently, impaired autophagy has been shown to
lead to a beneficial outcome in infectious models (102–104),
which represent a reverse situation in comparison to Mtb and
other strictly intracellular bacteria.
To conclude, activation of autophagy clearly seems to have
beneficial effects during infection withMtb, but for other bacteria
the effects might be different. Thus, it is important to delineate
the role of autophagy for specific bacteria since modulation of
autophagy could potentially lead to beneficial or detrimental
effects, depending on the context.
ANTIBIOTICS AND EFFECTS ON HOST
IMMUNITY
Antibiotic treatment is the natural first choice of treatment
against bacterial infections. The traditional paradigm considers
that antibiotic drugs specifically target bacteria. However, several
antibiotic drugs also affect innate immunity via direct effects
on host signaling pathways. The most potent antibiotic drug
classes in this respect are the quinolones, the macrolides and
drugs used for treatment of tuberculosis, mostly studied for the
first-line drug rifampicin. In this section, we include examples
of antibiotics that have been shown to have direct effects on
host immunity.
Ciprofloxacin, one of the best-studied antibiotics of the
quinolone class, was developed as a potent inhibitor of
topoisomerase 2 in bacteria. It is active against both gram-
positive and gram-negative bacteria. It is widely used by virtue
of its good and broad intracellular penetration effects and low
adverse event profile. However, resistance against ciprofloxacin
has emerged, and consequently the recommendations regarding
empirical use of this drug have been changed. In addition,
potentially serious adverse side effects are also increasingly
acknowledged. These side effects include cardiac arrhythmias,
tendon ruptures, and the selection for Clostridium difficile-
associated diarrhea (CDAD).
Ciprofloxacin has a direct bactericidal effect against bacteria
via the SOS-response, which releases large amounts of ROS,
causing DNA-damage, and bacterial death (105). Consequently,
scavengers of ROS inhibit the effects of ciprofloxacin, which
provide evidence for a ROS-dependent bacterial killing. It is
well-known that ciprofloxacin has profound effects on the
intestinal microbiome. In fact, an altered microbiota was evident
up to 1 year after treatment of ciprofloxacin (106, 107).
Clinical use of ciprofloxacin is associated with a higher risk
of developing CDAD, which could possibly be mediated via
direct effects on the microbiota (108). However, ciprofloxacin
has also been shown to downregulate colonic expression of
Frontiers in Immunology | www.frontiersin.org 8 June 2020 | Volume 11 | Article 1209
Bergman et al. Expression of Antimicrobial Peptides
AMPs (109). Recently, it was also shown that ciprofloxacin
caused a loss of the mucosal barrier and immune-function in
the intestine (110). Thus, it is becoming increasingly clear that
ciprofloxacin has potent and direct effects on innate immunity.
For example, ciprofloxacin has been shown to upregulate IL1-β
and TNF-α expression in humanmacrophages (111). In a clinical
study, patients with gram-negative sepsis that were treated
with ciprofloxacin exhibited lower levels of pro-inflammatory
cytokines, compared to those patients treated with a beta-
lactam antibiotic (112). To conclude, ciprofloxacin is widely
used and it has a profound impact on the microbiota. However,
ciprofloxacin also exerts immunomodulatory functions, which
may be beneficial (anti-inflammatory) or detrimental (down-
regulation of AMP-expression) depending on the circumstances.
Azithromycin (AZM) is a macrolide antibiotic drug targeting
the 50S subunit of the bacterial ribosome. It is widely used against
respiratory tract infections, since it is also active against atypical
bacteria, including Mycoplasma spp., atypical mycobacteria
and Legionella spp. It also has been extensively used as a
prophylactic drug in patients with asthma and bronchiectasis.
The prophylactic use of AZM was further substantiated recently
in a randomized and placebo-controlled trial, where the number
of asthma exacerbations was reduced, and the quality of life
was increased (113). A Cochrane review has also concluded that
there are beneficial effects of AZM in patients with bronchiectasis
(114). The drawbacks are the potential risk of the development of
resistance against AZM and adverse events, such as arrhythmias,
diarrhea, and arthralgia (115).
In addition to its bacterial target, AZM has potent immuno-
modulatory effects. These effects are considered to contribute
to its efficacy as a preventive agent in patients with respiratory
diseases. For example, it was recently shown that AZM protects
against Pseudomonas infections in the lung via direct inhibition
of the inflammasome (116). In addition, AZM polarizes
macrophages toward an M2 phenotype via inhibition of STAT1
and NFκB (117). AZM also contributes to the strengthening
of the barrier in the airways by induction of tight junction
proteins (118). Further, AZM induces epidermal differentiation,
which potentially can protect the lungs during infection (119).
Another layer of recently added complexity is that AZM was
shown to alter the microbiome and metabolome of the lung,
promoting bacterial metabolites with anti-inflammatory effects
of the airways. Finally, AZMmay protect against virus infections,
as shown in the context of zika-virus, where AZM induced
protective type 1 and type 3 interferon responses (120). The
antiviral effects of AZM could also explain the beneficial effects in
asthmatic patients, where rhinovirus often triggers exacerbations
(121). One way to reduce the problems with antibiotic resistance
is to use a macrolide analog without antimicrobial properties
but with retained anti-inflammatory effects. One such non-
antibiotic macrolide drug candidate was recently shown to
reduce inflammation in an allergy mouse model (122).
A third group of antibiotics with potent interactions with the
immune system is the TB-drugs. This has been best studied for
the first-line drug rifampicin (RIF), which has an impact on the
immune responses during TB-infection at several levels. One key
mechanism appears to involve direct interactions between RIF
and nuclear receptors. For example, it has been shown that RIF
activates pregnane X receptor (PXR) that can promote TB growth
in macrophages via increased efflux of TB-drugs out of the cell
(123). This leads to sustained bacterial growth in the presence
of the drug, which may accelerate the development of resistance.
Notably, M. tuberculosis with a single nucleotide polymorphism
in the rpoB-gene bypasses the protective IL1-β response and
instead promotes an interferon-β response. This causesmetabolic
reprogramming of macrophages, ultimately promoting bacterial
growth (124). A recent study links the aryl hydrocarbon receptor
(AhR) to TB-treatment. AhR is a member of the family of basic
helix-loop-helix transcription factors and can be activated by
tryptophan metabolites. RIF, and the related drug rifabutin, are
sensed by the AhR, leading to impaired phagocytosis of Mtb by
macrophages. The application of a small molecule inhibitor of
AhR caused decreased phagocytosis and improved killing of Mtb
(125). These findings collectively demonstrate that TB-drugs are
sensed by the innate immune system, which activate changes in
host cells that may be detrimental for the control of intracellular
bacterial growth. Nevertheless, the clinical implications of innate
immune sensing of TB-drugs remain to be shown. It should
be noted that rifampicin has been the most essential drug for
TB-treatment for decades. However, it is possible that drug
concentrations below the MIC-value will impair endogenous
defenses, as suggested by Puyskens et al. (125), which could play
a role in the resolution of infection.
CONCLUSION
Initial innate defenses at epithelial surfaces are complex and
include AMPs as important effectors. Many of the surface
effectors including ROS and NO are also present in phagocytes,
the second line of early defenses. The expression of AMPs is
included in the differentiation program of innate immune cells
but is also influenced by signals from the environment. Over the
last decade, it has emerged that metabolites from bacteria and
nutritional components are influential environmental mediators
for the expression of the innate immune effectors. These
innate components constitute an important barrier against
invading pathogenic microbes, preventing them from entering
the internal host environment. The strength of the barrier is
decisive for keeping microbes at bay and the environmental
signals are important for a tight barrier. Several pathogens
suppress the expression of barrier components and thereby
manage to open an entrance into the body, leading to infections.
Details behind the interactions between bacteria and host
cells must be resolved for each pathogen and much work
remains to be done. However, powerful analytical models
based on gene deletions in bacteria and host cells from
different organisms are developing fast and open up for novel
treatment approaches. A detailed knowledge on pathogen-
mediated suppression of innate immunity and the discovery
of counteracting compounds is the focus of our research. For
example, inducers of innate effector mechanisms may be used
alone or in combination with antibiotics. Such approaches would
likely reduce the spread of resistance strains. Future research
efforts on the interaction between multidrug-resistant bacteria
and the host is warranted. The use of host directed therapy
Frontiers in Immunology | www.frontiersin.org 9 June 2020 | Volume 11 | Article 1209
Bergman et al. Expression of Antimicrobial Peptides
holds the promise to promote health and reduce the spread of
antibiotic-resistant strains.
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